Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
DD.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
B.1.476NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.75.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.17.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BR.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.136NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.46NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.530NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAYNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XAENSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.633NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.357NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.404NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DW.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CV.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.570NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BP.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.1.73NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DJ.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.336NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.344NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
A.2.5.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.487NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.165NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.450NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.50NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.118NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.400.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.548NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.111NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.540NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.36.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.554NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.492NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.485NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.267NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.268NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.243.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22381.5US
AY.130NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.119NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AY.24.1 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.276NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.167NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.444NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used